ARECOR 2021 ANNUAL REPORT AND NOTICE OF AGM
Arecor Therapeutics plc
("Arecor" or the "Group")
POSTING OF ARECOR 2021 ANNUAL REPORT AND NOTICE OF AGM
Cambridge , UK, 27 April 2022. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that it has today published and posted to shareholders the Annual Report and Accounts for the year ended 31 December 2021 and Notice of the Annual General Meeting ("AGM") which will be held at Covington & Burling LLP, 22 Bishopsgate, London EC2N 4BQ , on 23 May 2022 at 1.00 p.m. (BST).
The Annual Report and Accounts and notice of AGM are also available to view on, and download from, the Company's website at www.arecor.com/investor-centre/ .
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR)
-ENDS-
For more information, please contact:
|
Arecor Therapeutics plc |
|
|
Dr Sarah Howell, Chief Executive Officer |
Tel: +44 (0) 1223 426060 Email: info@arecor.com |
|
|
|
|
Susan Lowther, Chief Financial Officer |
Tel: +44 (0) 1223 426060 Email: info@arecor.com |
|
|
|
|
Mo Noonan, Communications |
Tel: +44 (0) 7876 444977 Email: mo.noonan@arecor.com |
|
|
|
|
Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) |
Tel: +44 (0) 20 7886 2500
|
|
|
|
|
Consilium Strategic Communications |
|
|
Chris Gardner, David Daley, Angela Gray |
Tel: +44 (0) 20 3709 5700 Email: arecor@consilium-comms.com |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 16 hours ago IntegraFin Holding
- 16 hours ago Spirent Communications
- 16 hours ago CRH (CDI)
- 17 hours ago Bezant Resources
- 18 hours ago EJF Investments Ltd NPV